PBAC's latest decision on Dasatinib: Recommended with restriction (2019). Considered for Newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) in combination with chemotherapy or corticosteroids for induction and consolidation therapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
7
first 2007
Submissions
7
2007 → 2019
Eligible population
Adults aged 18 years and over with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia, treated with dasatinib in combination with chemotherapy or corticosteroids for induction and consolidation therapy.
Therapy area
Haematology
Line of therapy
First-line
Evidence base
Single-arm
Primary endpoint
Other
Pivotal trial size
247 patients
Comparator
imatinib
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as equivalent efficacy and safety assumed.
ICER (historical)
$45k/QALY–$105k/QALY in an earlier submission (2007) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2007: Recommended with restriction · Authority Required